M. Yashi, A. Nukui, S. Kurokawa, M. Ochi, S. Ishikawa, K. Goto, Y. Kobayashi, O. Muraishi and A. Tokue, “Elevated Serum Progastrin-Releasing Peptide (31 - 98) Level Is a Predictor of Short Response Duration after Hormonal Therapy in Metastatic Prostate Cancer,” Prostate, Vol. 56, 2003, pp. 305-312.

has been cited by the following article:

• TITLE: Neuroendocrine Differentiation in the Progression of Prostate Cancer: An Update on Recent Developments

  AUTHORS: Valérie Perrot

  KEYWORDS: Prostate Cancer; Hormonal Therapy; Neuroendocrine; Neuroendocrine Differentiation; Neuropeptides; Chromogranin A; Tumorigenesis; Adenocarcinoma

  JOURNAL NAME: Open Journal of Urology, Vol.2 No.3A, October 30, 2012

  ABSTRACT: Neuroendocrine (NE) differentiation, either benign or malignant, is the hallmark of prostate cancer (PCa). Clusters of malignant NE cells are found in most prostate cancer cases. NE differentiation is among the non-mutually exclusive theories proposed to explain the progression to androgen independence of PCa. NE differentiation is usually associated with an increased aggressivity and invasiveness of prostate tumors and a poor prognosis. This review aims to present an overview of current knowledge on neuroendocrine differentiation in PCa to improve our understanding of tumour progression and androgen independence. The NE component represents an important therapeutic axis. Development of new generation of drugs that selectively target NE-like cells may lead to the development of new therapeutic modalities for advanced and hormone-refractory PCa.